Part 2: Pharmacogenetic variability in drug transport and phase I anticancer drug metabolism

Oncologist

Volumn 16, Issue 6, 2011, Pages 820-834

  Deenen, Maarten J ^a   Cats, Annemieke ^a   Beijnen, Jos H ^b,c   Schellens, Jan H M ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Anticancer drugs; Drug transport; Oncology; Personalized medicine; Pharmacogenetics; Phase I metabolism

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; FLUOXETINE; GEFITINIB; IFOSFAMIDE; IMATINIB; INDISULAM; IRINOTECAN; METHOTREXATE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PAROXETINE; TAMOXIFEN; TAXANE DERIVATIVE; TENIPOSIDE; THALIDOMIDE; THIOTEPA; TOPOTECAN; TOREMIFENE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ABCB1 GENE; ABCG2 GENE; ACUTE GRANULOCYTIC LEUKEMIA; AREA UNDER THE CURVE; ARTICLE; BLMH GENE; BREAST CANCER; CANCER RESISTANCE; CDA GENE; CYP2B6 GENE; CYP2C19 GENE; CYP2C8 GENE; CYP2C9 GENE; CYP2D6 GENE; CYP3A4 GENE; CYP3A5 GENE; DIARRHEA; DPYD GENE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG METABOLISM; DRUG RESPONSE; DRUG TRANSFORMATION; DRUG TRANSPORT; GASTROINTESTINAL TUMOR; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; NEOPLASM; OVARY CANCER; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79959614317     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0259     Document Type: Article

References (160)

1. Thiebaut F, Tsuruo T, Hamada H et al. Cellular localization of the multi-drug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987;84:7735-7738.
2. Cordon-Cardo C, O'Brien JP, Casals D et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989;86:695-698.
3. Schuetz EG, Furuya KN, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995;275:1011-1018.
4. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003;43: 285-307.
5. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-3478.
6. Cascorbi I, Gerloff T, Johne A et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001;69:169-174.
7. Kim RB, Leake BF, Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-199.
8. Sai K, Kaniwa N, Itoda M et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 2003;13:741-757.
9. Kroetz DL, Pauli-Magnus C, Hodges LM et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003;13:481-494.
10. Siegsmund M, Brinkmann U, Schaffeler E et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002;13:1847-1854.
11. Hitzl M, Drescher S, van der Kuip H et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001;11:293-298.
12. Wang D, Johnson AD, Papp AC et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 34350T affects mRNA stability. Pharmaco-genet Genomics 2005;15:693-704.
13. Nakamura T, Sakaeda T, Horinouchi M et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002;71:297-303.
14. Illmer T, Schuler US, Thiede C et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62:4955-4962.
15. Han JY, Lim HS, Yoo YK et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007;110:138-147.
16. Isla D, Sarries C, Rosell R et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004;15:1194-1203.
17. Marsh S, Paul J, King CR et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007;25: 4528-4535.
18. Stanulla M, Schaffeler E, Arens S et al. GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. Int J Hematol 2005;81:39-44.
19. Kim DH, Park JY, Sohn SK et al. Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer 2006;118:2195-2201.
20. Maliepaard M, Scheffer GL, Faneyte IF et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-3464.
21. Cusatis G, Sparreboom A. Pharmacogenomic importance of ABCG2. Pharmacogenomics 2008;9:1005-1009.
22. Bäckström G, Taipalensuu J, Melhus H et al. Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. Eur J Pharm Sci 2003;18:359-364.
23. Bosch TM, Kjellberg LM, Bouwers A et al. Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population. Am J Pharmacogenomics 2005;5:123-131.
24. Zamber CP, Lamba JK, Yasuda K et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003;13:19-28.
25. Imai Y, Nakane M, Kage K et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002;1: 611-616.
26. Kobayashi D, Ieiri I, Hirota T et al. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 2005;33:94-101.
27. Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. Int J Cancer 2004;109:238-246.
28. Tamura A, Wakabayashi K, Onishi Y et al. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci 2007;98: 231-239.
29. Sparreboom A, Loos WJ, Burger H et al. Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol Ther 2005;4:650-658.
30. de Jong FA, Marsh S, Mathijssen RH et al. ABCG2 pharmacogenetics: Ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 2004;10:5889-5894.
31. Jada SR, Lim R, Wong CI et al. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 2007;98:1461-1467.
32. Gardner ER, Burger H, van Schaik RH et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 2006;80:192-201.
33. Petain A, Kattygnarath D, Azard J et al. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 2008;14:7102-7109.
34. Li J, Cusatis G, Brahmer J et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 2007;6:432-438.
35. Cusatis G, Gregorc V, Li J et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 2006;98:1739-1742.
36. Akasaka K, Kaburagi T, Yasuda S et al. Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer. Cancer Chemother Pharmacol 2010;66: 691-698.
37. Granvil CP, Madan A, Sharkawi M et al. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metab Dispos 1999;27:533-541.
38. Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphos-phorines. Clin Pharmacokinet 2000;38:291-304.
39. Rae JM, Soukhova NV, Flockhart DA et al. Triethylenethiophosphora-mide is a specific inhibitor of cytochrome P450 2B6: Implications for cyclophosphamide metabolism. Drug Metab Dispos 2002;30:525-530.
40. Jacobson PA, Green K, Birnbaum A et al. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol 2002;49:461-467.
41. Lang T, Klein K, Fischer J et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001;11:399-415.
42. Hiratsuka M, Takekuma Y, Endo N et al. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 2002;58:417-421.
43. Lamba V, Lamba J, Yasuda K et al. Hepatic CYP2B6 expression: Gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 2003;307:906-922.
44. Rotger M, Tegude H, Colombo S et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007;81:557-566.
45. Zukunft J, Lang T, Richter T et al. A natural CYP2B6 TATA box polymorphism (-82T-> C) leading to enhanced transcription and relocation of the transcriptional start site. Mol Pharmacol 2005;67:1772-1782.
46. Ariyoshi N, Miyazaki M, Toide K et al. A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactiva-tion. Biochem Biophys Res Commun 2001;281:1256-1260.
47. Jinno H, Tanaka-Kagawa T, Ohno A et al. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 2003;31:398-403.
48. Hofmann MH, Blievernicht JK, Klein K et al. Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 2008;325:284-292.
49. Hesse LM, He P, Krishnaswamy S et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 2004;14:225-238.
50. Xie HJ, Yasar U, Lundgren S et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 2003;3:53-61.
51. Xie H, Griskevicius L, Ståhle L et al. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Sci 2006; 27:54-61.
52. Nakajima M, Komagata S, Fujiki Y et al. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics 2007;17: 431-445.
53. Ekhart C, Doodeman VD, Rodenhuis S et al. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 2008;18:515-523.
54. Ekhart C, Rodenhuis S, Smits PH et al. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics 2008; 18:1009-1015.
55. Low SK, Kiyotani K, Mushiroda T et al. Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. J Hum Genet 2009;54:564-571.
56. Gor PP, Su HI, Gray RJ et al. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: A retrospective cohort study. Breast Cancer Res 2010;12:R26.
57. Kumar GN, Oatis JE Jr, Thornburg KR et al. 6 alpha-hydroxytaxol: Isolation and identification of the major metabolite of taxol in human liver microsomes. Drug Metab Dispos 1994;22:177-179.
58. Bahadur N, Leathart JB, Mutch E et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002;64:1579-1589.
59. Dai D, Zeldin DC, Blaisdell JA et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11:597-607.
60. Soyama A, Saito Y, Hanioka N et al. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol Pharm Bull 2001;24:1427-1430.
61. Henningsson A, Marsh S, Loos WJ et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005;11:8097-8104.
62. Marsh S, Somlo G, Li X et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 2007;7:362-365.
63. King BP, Khan TI, Aithal GP et al. Upstream and coding region CYP2C9 polymorphisms: Correlation with warfarin dose and metabolism. Pharmacogenetics 2004;14:813-822.
64. Shintani M, Ieiri I, Inoue K et al. Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: In vitro and in vivo studies. Clin Pharmacol Ther 2001;70:175-182.
65. Takanashi K, Tainaka H, Kobayashi K et al. CYP2C9 Ile359 and Leu359 variants: Enzyme kinetic study with seven substrates. Pharmacogenetics 2000;10:95-104.
66. Timm R, Kaiser R, Lötsch J et al. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J 2005;5:365-373.
67. Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-39.
68. Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007;25:5187-5193.
69. Jernström H, Bågeman E, Rose C et al. CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients. Br J Cancer 2009;101:1817-1823.
70. Zandvliet AS, Huitema AD, Copalu W et al. CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. Clin Cancer Res 2007;13:2970-2976.
71. Ando Y, Price DK, Dahut WL et al. Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther 2002;1:669-673.
72. De Morais SM, Wilkinson GR, Blaisdell J et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-598.
73. Li Y, Hou J, Jiang H et al. Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma. Haematologica 2007;92:1246-1249.
74. Dehal SS, Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 1997;57:3402-3406.
75. Johnson MD, Zuo H, Lee KH et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004;85:151-159.
76. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. CYP2D6 Allele Nomenclature. Available at http://www.cypalleles.ki.se/cyp2d6.htm, accessed June 26, 2010.
77. Aklillu E, Persson I, Bertilsson L et al. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996;278:441-446.
78. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005;5:6-13.
79. Johansson I, Lundqvist E, Bertilsson L et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993;90:11825-11829.
80. Hanioka N, Kimura S, Meyer UA et al. The human CYP2D locus associated with a common genetic defect in drug oxidation: A G1934-A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site. Am J Hum Genet 1990;47:994-1001.
81. Gjerde J, Hauglid M, Breilid H et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 2008;19:56-61.
82. Borges S, Desta Z, Li L et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006;80:61-74.
83. Bijl MJ, van Schaik RH, Lammers LA et al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat 2009;118:125-130.
84. Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101:113-121.
85. Kiyotani K, Mushiroda T, Sasa M et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008;99:995-999.
86. Newman WG, Hadfield KD, Latif A et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 2008; 14:5913-5918.
87. Schroth W, Goetz MP, Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009;302:1429-1436.
88. Xu Y, Sun Y, Yao L et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 2008;19:1423-1429.
89. Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-9318.
90. Nowell SA, Ahn J, Rae JM et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005;91:249-258.
91. Wegman P, Vainikka L, Stål O et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005;7:R284-R290.
92. Wegman P, Elingarami S, Carstensen J et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007;9:R7.
93. Okishiro M, Taguchi T, Jin Kim S et al. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 2009;115:952-961.
94. Sideras K, Ingle JN, Ames MM et al. Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol 2010;28:2768-2776.
95. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharma-cogenetics and cancer. Oncogene 2006;25:1679-1691.
96. Li J, Zhao M, He P et al. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007;13:3731- 3737.
97. Guengerich FP. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17.
98. Ozdemir V, Kalow W, Tang BK et al. Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method. Pharmacogenetics 2000;10:373-388.
99. Wojnowski L, Kamdem LK. Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol 2006;2:171-182.
100. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. CYP3A4 Allele Nomenclature. Available at http://www.cypalleles.ki.se/cyp3a4.htm, accessed June 28, 2010.
101. Rodriguez-Antona C, Sayi JG, Gustafsson LL et al. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analysesof variant CYP3A4 alleles. Biochem Biophys Res Com-mun 2005;338:299-305.
102. Hustert E, Haberl M, Burk O et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773-779.
103. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-391.
104. Shou M, Martinet M, Korzekwa KR et al. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: Enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 1998;8:391-401.
105. Tran A, Jullien V, Alexandre J et al. Pharmacokinetics and toxicity of do-cetaxel: Role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006;79:570-580.
106. Baker SD, Verweij J, Cusatis GA et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 2009;85:155-163.
107. Lewis LD, Miller AA, Rosner GL et al. A comparison of the pharmaco-kinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res 2007;13: 3302-3311.
108. Gréen H, Söderkvist P, Rosenberg Pet al. Pharmacogenetic studiesof pac-litaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 2009;104:130-137.
109. Petros WP, Hopkins PJ, Spruill S et al. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol 2005;23:6117-6125.
110. Pillot GA, Read WL, Hennenfent KL et al. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacog-enomic analysis: Final report. J Thorac Oncol 2006;1:972-978.
111. Rudin CM, Liu W, Desai A et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 2008;26:1119-1127.
112. Ingelman-Sundberg M, Sim SC, Gomez A et al. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepi-genetic and clinical aspects. Pharmacol Ther 2007;116:496-526.
113. Sahin M, Sahin E, Gümüslü S. Cyclooxygenase-2incancer and angiogen-esis. Angiology 2009;60:242-253.
114. Clevers H. Colon cancer-understanding how NSAIDs work. N Engl J Med 2006;354:761-763.
115. Aparicio Gallego G, Diaz Prado S, Jiménez Fonseca P et al. Cyclooxy-genase-2 (COX-2): A molecular target in prostate cancer. Clin Transl Oncol 2007;9:694-702.
116. Seitz HK, Becker P. Alcohol metabolism and cancer risk. Alcohol Res Health 2007;30:38-47.
117. Yokoyama A, Omori T. Genetic polymorphisms of alcohol and aldehyde dehydrogenases and risk for esophageal and head and neck cancers. Alcohol 2005;35:175-185.
118. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16:215-237.
119. Heggie GD, Sommadossi JP, Cross DS et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987;47:2203-2206.
120. Boisdron-Celle M, Remaud G, Traore S et al. 5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007;249:271-282.
121. Maekawa K, Saeki M, Saito Y et al. Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. J Hum Genet 2007;52:804-819.
122. Meinsma R, Fernandez-Salguero P, Van Kuilenburg AB et al. Human polymorphism in drug metabolism: Mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol 1995;14:1-6.
123. Wei X, McLeod HL, McMurrough J et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996;98:610-615.
124. Vreken P, Van Kuilenburg AB, Meinsma R et al. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis 1996;19:645-654.
125. Mattison LK, Johnson MR, Diasio RB. A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA: Conservation of functional domains and relevance to genetic polymorphisms. Pharmaco-genetics 2002;12:133-144.
126. Van Kuilenburg AB, Haasjes J, Richel DJ et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-4712.
127. Dobritzsch D, Schneider G, Schnackerz KD et al. Crystal structure of di hydropyrimidine dehydrogenase, a major determinant of the pharmacoki-netics of the anti-cancer drug 5-fluorouracil. EMBO J 2001;20:650-660.
128. Blasco H, Boisdron-Celle M, Bougnoux P et al. A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient. Br J Clin Pharmacol 2008;65:966-970.
129. Ezzeldin H, Johnson MR, Okamoto Y et al. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res 2003;9:3021-3028.
130. Johnson MR, Hageboutros A, Wang K et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999;5:2006-2011.
131. Saif MW, Ezzeldin H, Vance K et al. DPYD*2A mutation: The most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol 2007;60:503-507.
132. Steiner M, Seule M, Steiner B et al. 5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: Report of a case. J Clin Pathol 2005;58:553-555.
133. Van Kuilenburg AB, Vreken P, Beex LV et al. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur J Cancer 1997;33: 2258-2264.
134. Van Kuilenburg AB, Muller EW, Haasjes J et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of the common IVS14+ 1G>A mutation causing DPD deficiency. Clin Cancer Res 2001; 7:1149-1153.
135. Van Kuilenburg AB, Meinsma R, Zoetekouw L et al. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002;12:555-558.
136. Maring JG, Van Kuilenburg AB, Haasjes J et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 2002;86:1028-1033.
137. Raida M, Schwabe W, Haüsler P et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res 2001;7: 2832-2839.
138. Morel A, Boisdron-Celle M, Fey L et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006;5:2895-2904.
139. Braun MS, Richman SD, Thompson L et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: The FOCUS trial. J Clin Oncol 2009;27: 5519-5528.
140. Largillier R, Etienne-Grimaldi MC, Formento JL et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res 2006; 12:5496-5502.
141. Schwab M, Zanger UM, Marx C et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26:2131-2138.
142. Deenen MJ, Tol J, Burylo AM et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 2011, in press.
143. Boige V, Mendiboure J, Pignon JP et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol 2010;28:2556-2564.
144. Gilbert JA, Salavaggione OE, Ji Y et al. Gemcitabine pharmacogenomics: Cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006;12:1794-1803.
145. Kirch HC, Schröder J, Hoppe H et al. Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol 1998;26:421-425.
146. Tibaldi C, Giovannetti E, Vasile E et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008;14:1797-1803.
147. Yue L, Saikawa Y, Ota K et al. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 2003;13:29-38.
148. Sugiyama E, Lee SJ, Lee SS et al. Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene. Drug Metab Phar-macokinet 2009;24:553-556.
149. Sugiyama E, Kaniwa N, Kim SR et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: The impact of a cytidine deaminase polymorphism. J Clin Oncol 2007;25:32-42.
150. Yonemori K, Ueno H, Okusaka T et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 2005;11:2620-2624.
151. Ueno H, Kaniwa N, Okusaka T et al. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br J Cancer 2009;100:870-873.
152. Mercier C, Raynal C, Dahan L et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics 2007;17:841-844.
153. Maring JG, Wachters FM, Slijfer M et al. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: Impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol 2010;66:611-617.
154. Koldamova RP, Lefterov IM, Gadjeva VG et al. Essential binding and functional domains of human bleomycin hydrolase. Biochemistry 1998; 37:2282-2290.
155. Morris G, Mistry JS, Jani JP et al. Neutralization of bleomycin hydrolase by an epitope-specific antibody. Mol Pharmacol 1992;42:57-62.
156. Brömme D, Rossi AB, Smeekens SP et al. Human bleomycin hydrolase: Molecular cloning, sequencing, functional expression, and enzymatic characterization. Biochemistry 1996;35:6706-6714.
157. Tuimala J, Szekely G, Gundy S et al. Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: Role in mutagen sensitivity. Carcinogenesis 2002;23:1003-1008.
158. de Haas EC, Zwart N, Meijer C et al. Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer. J Clin Oncol 2008;26:1817-1823.
159. Nauck M, Gierens H, März W et al. Rapid detection of a common dihy-dropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxicity and congenital thymine uraciluria using fluorogenic hybridization probes. Clin Biochem 2001;34:103-105.
160. Seck K, Riemer S, Kates R et al. Analysisof the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res 2005;11:5886-5892.